← Back to Screener
Boundless Bio, Inc. Common Stock (BOLD)
Price$1.44
Momentum ScoreB
Favorite Metrics
Price vs S&P 500 (26W)14.70%
Price vs S&P 500 (4W)-12.62%
VGM Score65.58
Market Capitalization$32.57M
All Metrics
Book Value / Share (Quarterly)$3.86
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-2.12
Price vs S&P 500 (YTD)9.90%
EPS (TTM)$-2.50
10-Day Avg Trading Volume0.09M
EPS Excl Extra (TTM)$-2.50
EPS (Annual)$-2.60
ROI (Annual)-58.99%
Cash / Share (Quarterly)$4.14
ROA (Last FY)-37.05%
EBITD / Share (TTM)$-2.66
ROE (5Y Avg)-47.13%
Cash Flow / Share (Annual)$-2.11
P/B Ratio0.38x
P/B Ratio (Quarterly)0.29x
Net Income / Employee (Annual)$-2,078,500
ROA (TTM)-34.66%
EPS Incl Extra (Annual)$-2.60
Current Ratio (Annual)8.74x
Quick Ratio (Quarterly)9.69x
3-Month Avg Trading Volume0.19M
52-Week Price Return23.93%
Revenue / Employee (TTM)$0
52-Week High$1.68
EPS Excl Extra (Annual)$-2.60
26-Week Price Return30.63%
Quick Ratio (Annual)8.58x
13-Week Price Return25.00%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)9.87x
Enterprise Value$15.09M
Revenue / Employee (Annual)$0
Cash / Share (Annual)$4.80
3-Month Return Std Dev74.53%
Net Income / Employee (TTM)$-1,999,800
ROE (Last FY)-58.99%
EPS Basic Excl Extra (Annual)$-2.60
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.50
ROI (TTM)-53.60%
Revenue / Share (Annual)$0.00
Price vs S&P 500 (52W)-4.27%
Year-to-Date Return20.83%
5-Day Price Return0.69%
EPS Normalized (Annual)$-2.60
ROA (5Y Avg)-37.74%
Month-to-Date Return-0.68%
EBITD / Share (Annual)$-2.79
ROI (5Y Avg)-47.13%
EPS Basic Excl Extra (TTM)$-2.50
P/B Ratio (Annual)0.27x
Book Value / Share (Annual)$4.40
Price vs S&P 500 (13W)15.25%
Beta1.68x
Revenue / Share (TTM)$0.00
ROE (TTM)-53.60%
52-Week Low$0.96
mGradeB
vgmGradeB
Show chart for
Earnings Surprise History
Q1 26-0.60est. -0.59
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
2.29
2.29
2.29
2.29
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
BOLDBoundless Bio, Inc. Common Stock | — | — | B | $1.44 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Boundless Bio is a clinical-stage oncology company developing therapeutics that target extrachromosomal DNA (ecDNA), a driver of oncogene amplification in cancer. The company's lead program, BBI-355, is an oral CHK1 inhibitor designed to disrupt ecDNA replication and transcription, addressing an unmet need in patients with oncogene-amplified tumors.